Voluntary nationwide recall: Famotidine (Fresenius – November)

Nov. 2025Pharmacy Updates

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.

This drug is being recalled because the level of a bacteria component called endotoxin was higher than the acceptable range in one sample. Using a product with elevated endotoxin may cause nonserious reactions such as chills, change in mental status, change in breathing status, fever, increase in body temperature, shivering, and shaking. It may also cause severe reactions such as sepsis and septic shock or may lead to death.

As of Nov. 7, the nonserious reactions mentioned above were reported with one lot. There had been no reports of adverse events related to the second and third lots.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Famotidine or are experiencing any problems that may be related to receiving the product, you should stop using it and talk to your doctor.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Fresenius Kabi USA Quality Assurance at 866-716-2459. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

UPMC Dental Advantage celebrates 15-years of growth

From pilot program to now serving all product lines
Jan. 2026What's New

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Jan. 2026Important Notices

Important: Expedited appeals fax requirement

Please remember that you must adhere to the designated process for submitting expedited appeals to have them processed in a timely manner. Follow these guidelines to help you successfully submit expedited appeals:
Jan. 2026Important Notices